Biocytogen Pharmaceuticals-B(02315) has reached a strategic cooperation with SIHUAN PHARM(00460) to accelerate research and development of innovative drugs in multiple areas such as weight loss.

Biocytogen Pharmaceuticals-B (02315) announced that the company has reached a strategic cooperation agreement with SIHUAN PHARM (00460). According to the agreement, the two parties will leverage Biocytogen Pharmaceuticals' leading fully human antibody development platform, combined with SIHUAN PHARM's deep expertise in drug development, production, and commercialization, to collaborate and exchange in the research and development of innovative drugs in multiple disease areas such as weight loss, driving synergies and establishing a long-term, stable partnership. SIHUAN PHARM highly recognizes the technical strength of Biocytogen Pharmaceuticals' platform. In this collaboration, Biocytogen Pharmaceuticals will leverage its independently developed model animals and efficacy platforms, fully human antibody discovery platform, and AI-driven antibody drug development platform, providing strong support for future cooperation between the two parties. By integrating the capabilities of both parties in innovative research and industrial transformation, the collaboration is expected to further enhance the efficiency of innovative drug development. Dr. Shen Yuelei, Chairman and CEO of Biocytogen Pharmaceuticals, said, "We are pleased to establish a strategic partnership with SIHUAN PHARM. SIHUAN PHARM has solid industry foundation and rich experience in drug development, production, and commercialization. Leveraging our independently developed fully human antibody discovery platform, Biocytogen Pharmaceuticals has established a systematic layout in various innovative treatment areas such as bispecific/multispecific antibodies, ADCs, nanobodies, and TCR, providing original innovation support for global innovative drug research and development. This cooperation will help both parties expand a broader cooperation space in multiple disease areas and further demonstrate the high recognition of industry partners for the technical strength of Biocytogen Pharmaceuticals' platform."